Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Amedisys ( AMED – Research Report ) today and set a price target of $215.00 . The company’s shares closed last Friday at $186.50.
Geode Capital Management LLC increased its holdings in shares of Community Health Systems (NYSE:CYH) by 13.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchan
Community Health to sell majority interest in Florida hospital CYH

Community Health sells two Texas hospitals CYH

09:16am, Monday, 27'th Apr 2020
Community Health sells two Texas hospitals CYH
AEGON USA Investment Management LLC trimmed its position in shares of Community Health Systems (NYSE:CYH) by 12.4% during the first quarter, according to its most recent Form 13F filing with the SEC.
Community Health Systems (NYSE:CYH) – Analysts at Jefferies Financial Group lowered their Q1 2020 earnings per share (EPS) estimates for shares of Community Health Systems in a note issued to invest
Community Health Systems, Inc. (the "Company") (NYSE: CYH) today announced a change in the location of its annual meeting of stockholders for 2020 (the "Annual Meeting") from in-person to a virtual-on

Phreesia (PHR) Received its Third Buy in a Row

04:37pm, Friday, 24'th Apr 2020
After KeyBanc and Robert W. Baird gave Phreesia (NYSE: PHR) a Buy rating last month, the company received another Buy, this time from Raymond James.
Community Health Systems (NYSE:CYH) saw a significant decline in short interest in March. As of March 31st, there was short interest totalling 18,800,000 shares, a decline of 7.1% from the March 15th
News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium.
Community Health Systems (CYH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Community Health Systems (CYH) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In a report released yesterday, Steven Valiquette from Barclays maintained a Buy rating on Sabra Healthcare REIT (SBRA), with a price target of $16.00.
In a report released yesterday, Steven Valiquette from Barclays maintained a Buy rating on Sabra Healthcare REIT (SBRA – Research
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE